Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC1118 with Irinotecan or FOLFIRI in Solid Tumors
NCT03454620Phase 2Completed
- Sponsor
- GC Biopharma
- Start
- Apr 2018
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of GC1118 in solid tumor, colorectal cancer (CRC), gastric cancer (GC), sponsored by GC Biopharma. Started Apr 2018; status: completed.
02
Drugs
GC1118
03
Conditions
solid tumorcolorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03454620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454620.